Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion

Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.